Michael E. Jolley
Diachemix LLC
683 East Center Street
Unit H
Grayslake
IL 60030
USA

Dr Jolley received his BSc (1969) and PhD (1972) in chemistry from the University of Birmingham (UK). His doctoral thesis was on the mechanism of action of the glucoamylases from *A. niger*. From 1972-1974 he was a visiting fellow with Dr. C. P. J. Glaudemans in the Laboratory of Chemistry, NIAADD, National Institutes of Health, Bethesda, MD., where, in collaboration with Dr. M. Potter, NCI, he studied the carbohydrate-binding specificities of a family of homogeneous murine myeloma proteins (now called monoclonal antibodies) with anti-galactan specificities. After a year as a junior lecturer (1974-1975) in the Chemistry Department at the University of Birmingham (UK) he joined Abbott Laboratories Diagnostics Division (North Chicago, Il, 1976). While at Abbott, he worked on the initial development of enzyme immunoassays for hepatitis B surface antigen, carcinoembryonic antigen and the detection of antibodies to rubella virus. He also worked on a variety of isotopic and nonisotopic immunoassay formats and was instrumental in the development of the TDx, a totally automated fluorescence polarization system for the measurement of therapeutic drug levels and the detection of drugs of abuse in human body fluids. He left Abbott in 1982 to cofound Pandex Laboratories, where he invented particle concentration fluorescence immunoassay (PCFIA), the "Screen Machine" and the FCA (instruments for performing PCFIA). Pandex was acquired by Baxter Healthcare Corp. in 1986 and Dr Jolley became Senior Research Fellow with the responsibility for the identification, evaluation and development of new technology as it pertained to health care in general. Pandex Division was closed down in January 1992 and Dr Jolley founded Jolley Consulting and Research Inc (JCR) in March 1992. JCR was the first company to produce a 96-well fluorescence polarization instrument (the FFPM-2), which was used successfully by a number of major pharmaceutical companies in the mid 1990s for the high throughput screening of potential drug leads. In 1998 he became Scientific Director and co-founder of Diachemix Corporation (now Diachemix LLC), which uses fluorescence polarization in the animal health and food safety fields. He has been an invited speaker at many national and international conferences on drug discovery.